<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00012181</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01854</org_study_id>
    <secondary_id>ADVL0017</secondary_id>
    <secondary_id>CCG-AO972</secondary_id>
    <secondary_id>CDR0000068491</secondary_id>
    <secondary_id>COG-ADVL0017</secondary_id>
    <secondary_id>NCI-A0972</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <nct_id>NCT00012181</nct_id>
  </id_info>
  <brief_title>Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas</brief_title>
  <official_title>A PHASE I STUDY OF FLAVOPIRIDOL (NSC# 649890; IND# 46211) IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC SOLID TUMORS OR LYMPHOMAS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop&#xD;
      growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children&#xD;
      who have relapsed or refractory solid tumors or lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of flavopiridol in children with relapsed or&#xD;
      refractory solid tumors or lymphomas.&#xD;
&#xD;
      II. Determine the toxic effects and pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      III. Determine the antitumor activity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3 to 6 patients receive escalating doses of flavopiridol until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD defined as the dose at which fewer than one-third of patients experience DLT assessed using Common Toxicity Criteria version 2.0</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Recurrent Childhood Brain Stem Glioma</condition>
  <condition>Recurrent Childhood Cerebellar Astrocytoma</condition>
  <condition>Recurrent Childhood Cerebral Astrocytoma</condition>
  <condition>Recurrent Childhood Ependymoma</condition>
  <condition>Recurrent Childhood Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Liver Cancer</condition>
  <condition>Recurrent Childhood Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Childhood Malignant Germ Cell Tumor</condition>
  <condition>Recurrent Childhood Medulloblastoma</condition>
  <condition>Recurrent Childhood Rhabdomyosarcoma</condition>
  <condition>Recurrent Childhood Small Noncleaved Cell Lymphoma</condition>
  <condition>Recurrent Childhood Soft Tissue Sarcoma</condition>
  <condition>Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Childhood Visual Pathway and Hypothalamic Glioma</condition>
  <condition>Recurrent Childhood Visual Pathway Glioma</condition>
  <condition>Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Neuroblastoma</condition>
  <condition>Recurrent Osteosarcoma</condition>
  <condition>Recurrent Retinoblastoma</condition>
  <condition>Recurrent Wilms Tumor and Other Childhood Kidney Tumors</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (alvocidib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alvocidib)</arm_group_label>
    <other_name>FLAVO</other_name>
    <other_name>flavopiridol</other_name>
    <other_name>HMR 1275</other_name>
    <other_name>L-868275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (alvocidib)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed relapsed or refractory solid tumor or lymphoma including:&#xD;
&#xD;
               -  Neuroblastoma&#xD;
&#xD;
               -  Osteosarcoma&#xD;
&#xD;
               -  Ewing's sarcoma&#xD;
&#xD;
               -  Rhabdomyosarcoma&#xD;
&#xD;
               -  Wilms tumor&#xD;
&#xD;
               -  CNS tumors&#xD;
&#xD;
          -  Histological verification not required for brainstem tumors&#xD;
&#xD;
          -  No acute leukemia&#xD;
&#xD;
          -  Not eligible for higher priority COG phase I/II study&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% (over age 10)&#xD;
&#xD;
          -  Performance status - Lansky 50-100% (age 10 and under)&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL (transfusion allowed)&#xD;
&#xD;
          -  No granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow involvement&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
          -  SGPT no greater than 5 times normal&#xD;
&#xD;
          -  Albumin at least 2 g/dL&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate at least lower limit&#xD;
             of normal&#xD;
&#xD;
          -  Shortening fraction at least 27% by echocardiogram&#xD;
&#xD;
          -  Ejection fraction at least 50% by MUGA&#xD;
&#xD;
          -  Stable neurologic deficits within the past 2 weeks for patients with CNS tumors&#xD;
&#xD;
          -  CNS toxicity less than grade 2&#xD;
&#xD;
          -  No active graft-versus-host disease&#xD;
&#xD;
          -  No active uncontrolled infection or other serious medical condition&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  At least 7 days since prior biologic therapy and recovered&#xD;
&#xD;
          -  Prior bone marrow or stem cell transplantation allowed&#xD;
&#xD;
          -  At least 6 months since prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  At least 1 week since prior growth factors&#xD;
&#xD;
          -  No concurrent immunomodulating agents&#xD;
&#xD;
          -  At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)&#xD;
             and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  Concurrent dexamethasone for CNS tumors allowed if on stable dose for at least 2 weeks&#xD;
             prior to study&#xD;
&#xD;
          -  Concurrent corticosteroids allowed only for increased intracranial pressure in&#xD;
             patients with CNS tumors&#xD;
&#xD;
          -  At least 2 weeks since prior local (small port) palliative radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy to 50% or more of the pelvis&#xD;
&#xD;
          -  At least 6 months since prior craniospinal radiotherapy&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy except localized palliative radiotherapy&#xD;
&#xD;
          -  No concurrent anticonvulsants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Whitlock</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>COG Phase I Consortium</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>March 3, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
    <mesh_term>Retinoblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

